Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Zaleplon plus escitalopram for mild to moderate depression with insomnia
ChiCTR2500099466Phase 4Not yet recruiting
- Sponsor
- First Affiliated Hospital of Shanxi Medical University
- Start
- Mar 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of zaleplon and escitalopram in major depressive disorder (MDD) and Insomnia (2 arms), sponsored by First Affiliated Hospital of Shanxi Medical University. Primary endpoints: Insomnia Severity Index and Pittsburgh Sleep Quality Index. Planned start Mar 2025; status: not yet recruiting.
02
Drugs
zaleplonescitalopram
03
Conditions
major depressive disorder (MDD)Insomnia
Beyond the preview
Go deeper on ChiCTR2500099466.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2500099466.